Trending

24/7 MN – (NASDAQ: ANVS) wins FDA approval for late state Parkinson’s candidate. Shares are also up 22% $16.22 this morning on 5100 shares. And closing in on half a million shares in volume

FDA Allows Annovis Bio To Proceed With Phase 3 Study Of Buntanetap In Parkinson’s Disease

https://www.nasdaq.com/articles/fda-allows-annovis-bio-to-proceed-with-phase-3-study-of-buntanetap-in-parkinsons-disease

RelatedNews

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist